Relmada Therapeutics surges premarket as bladder cancer drug shows promising mid‑stage data

Relmada Therapeutics

09/03/2026 11:32

** Shares of drug developer Relmada Therapeutics RLMD.O rise 73% to $5.64 premarket

** Co says its experimental bladder cancer drug NDV-01 helped most patients stay cancer-free in a mid-stage study

** Co says 76% of 48 high-risk patients had no cancer after one year; 95% showed a complete response at some point

** No patients' disease worsened and none needed bladder removal surgery; side effects mostly mild, co adds

** Bladder cancer occurs when abnormal cells grow in the bladder lining; most early cases tend to return after treatment

** RLMD plans to start late‑stage trials later this year, with initial results expected by year‑end, co says

** Shares up about nine-fold in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))